We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Bioquell | LSE:BQE | London | Ordinary Share | GB0004992003 | ORD 10P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 597.00 | 0.00 | 00:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Jan 2020 to Jan 2025
TIDMBQE
RNS Number : 3133P
Bioquell PLC
25 May 2018
25 May 2018
Bioquell PLC - Disposal of Defence Business
Bioquell PLC ("Bioquell") (LSE symbol: BQE) - a leading provider of products and services for the Life Sciences, Pharmaceutical and Healthcare markets today announces the disposal of its MDH Defence business ("MDH").
Under the terms of the disposal, MDH is being sold for an initial consideration of GBP0.4m, with a further contingent payment of up to GBP0.6m due if MDH is successful in winning a specific contract for which it is presently bidding within the next 12 months. Bioquell will complete a partly fulfilled defence contract which will generate revenue and margin of approximately GBP0.7m and GBP0.2m respectively during the second half of 2018.
In the year ended 31 December 2017, MDH had revenue of GBP0.7m and made an operating loss of GBP35,000. The value of MDH's net assets being disposed of at completion is GBP0.4 million and any gain or loss on disposal will not be material, save to the extent that contingent consideration is received. MDH has no shared products or shared customers with Bioquell's core business.
Commenting on the strategic disposal, Ian Johnson, Executive Chairman of Bioquell PLC, said:
"I am pleased to have been able to reach agreement to exit this non-core business. The disposal represents a further step in simplifying and reducing the complexity of the business and transitioning Bioquell's focus to its core products and services, namely; bio-decontamination, aseptic workstations and infection control enclosures."
Enquiries:
Ian Johnson Executive Chairman Bioquell PLC 01264 835900
Michael Roller Finance Director
***********************************************
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
DISAAMRTMBMTMJP
(END) Dow Jones Newswires
May 25, 2018 03:05 ET (07:05 GMT)
1 Year Bioquell Chart |
1 Month Bioquell Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
